Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02073214
Other study ID # PB-DM/SBK-NEC-01/11
Secondary ID
Status Completed
Phase N/A
First received February 25, 2014
Last updated February 25, 2014
Start date April 2012
Est. completion date December 2013

Study information

Verified date February 2014
Source IBSS Biomed S.A.
Contact n/a
Is FDA regulated No
Health authority Poland: Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study was to evaluate the safety of a probiotic foodstuff and its influence on emergence and development of natural intestinal flora and the clinical status of premature very low birth weight neonates. The study was also intended to investigate reduction of colonisation by pathogenic bacteria and to estimate the incidence of gastrointestinal disorders.

Probotic bacteria contained in the investigational product administered directly after birth are beneficial for the development of normal gut microflora and can prevent or significantly limit gastrointestinal colonisation by pathogenic bacteria and the development of pathogenic flora in a hospital setting. Permanent colonisation with commensal flora in very early life improves gastrointestinal function in premature neonates by reducing the onset of or by decreasing the severity of the signs and symptoms of feeding intolerance and generalised bacterial infections, including sepsis and necrotizing enterocolitis.


Description:

Neonates defined as having very low birth weight (VLBW) are found to have a number of conditions typical for this period of life and body weight at birth. Perinatal and neonatal infections are relatively common in these babies, which can be attributed to their immunological immaturity (immature cellular or humoral immune responsiveness) and insufficient gastrointestinal tract colonisation by non-pathogenic bacteria, the presence of which depends on the type of delivery, feeding and environment in which the neonates are nursed.

Neonates admitted to neonatal intensive care units, particularly low birth-weight neonates born prematurely or with congenital disorders, are most susceptible. Probiotics administered to neonates are known to compete with pathogenic bacteria for essential nutrients and receptor sites, and to enzymatically modify toxin receptors. They are also known to produce antimicrobial substances, acidify the intestinal environment and stimulate the immune system, helping it reach full maturity. These are the reasons why intestinal microflora normalisation with the help of probiotics can be beneficial for VLBW neonates, especially those requiring intensive medical care.

In a review of clinical studies on the use of probiotics in NEC prevention in neonates, demonstrated beneficial effects of probiotics in a group of VLBW neonates compared to placebo. There are scientific reasons to believe that probiotics administered to neonates modulate the composition of the gut flora colonising the intestinal tract and are beneficial for the development and maturity of the immune system. In hitherto clinical studies, specific probiotic strains were found to provide beneficial effects by limiting infections in the neonatal period, including necrotizing enterocolitis in VLBW neonates.

The purpose of this multicentre, randomized study was to investigate whether the use of a probiotic preparation containing Lactobacillus rhamnosus KL53A and Bifidobacterium breve PB04 influence on emergence and development of natural intestinal flora and the clinical status of premature very low birth weight neonates and reduction of colonisation by pathogenic bacteria and to estimate the incidence of gastrointestinal disorders. The study took place between April 2012 and July 2013 in eight study centres in Poland. It was conducted in accordance with the original protocol and according to ICH-GCP requirements.

The duration of subject's participation in the trial was approximately 49 days, or until they were withdrawn or discharged from the hospital, whichever came earlier, prior to day 49.

As the trial did not concern medicinal product but the foodstuff (food for special medical purpose) it did not require Authority approval but was only subject to relevant Ethics Committee approval.

The study only included neonates who fulfilled the eligibility criteria, after obtaining an informed consent from their parents/legal guardians, to have their baby enrolled in the study and randomized into one of the two study groups: probiotic or placebo. Investigational product were administered during the first 48h of life, at the time of the enteral feed.

Efficacy evaluation was to determine whether the investigational product positively influences the emergence and progressive development of the natural gut flora and the clinical status of preterm VLBW neonates. As part of the efficacy evaluation, it was also examined whether the probiotic agent has the capacity to inhibit pathogenic colonisation and to reduce the incidence of gastrointestinal disorders, as compared to placebo.

Safety was evaluated by determining whether investigational product in VLBW preterm neonates increases AE/SAE incidence and influences the type of adverse events and serious adverse events as compared to placebo.


Recruitment information / eligibility

Status Completed
Enrollment 182
Est. completion date December 2013
Est. primary completion date July 2013
Accepts healthy volunteers No
Gender Both
Age group N/A to 48 Hours
Eligibility Inclusion Criteria:

1. Infants = 750 g and = 1800 g at birth

2. Gestational age of = 34 weeks

3. Mother's age = 18 years

4. Possibility of feeding by enteral route

5. Possibility of enrolment = 48 hours of age

6. Caucasian race

7. Parent-legal guardian informed consent obtained in writing

Exclusion Criteria:

1. Infants < 750 g and > 1800 g at birth

2. Gestational age of > 34 weeks

3. Mother's age < 18 years

4. Contraindicated to enteral nutrition within the first 48 hours of life

5. Birth asphyxia (Apgar score: 0-3)

6. Major congenital abnormalities, including gastrointestinal abnormalities

7. Severe clinical condition / disorders which the Investigator considers a contraindication to study participation, including the presence of at least 3 out of 4 of the following symptoms:

1. necessity of mechanical ventilation and FiO2 more than 0.6 elevation to maintain blood oxygen saturation within 88-93%,

2. metabolic acidosis, pH less than 7.20 and BE more than (-10),

3. necessity of vasopressor (antihypotensive) agents to maintain proper arterial blood pressure,

4. signs of damage to at least one vital organ (liver, kidneys, gastrointestinal tract, adrenal glands).

8. Administration of other probiotic preparations

9. Enrolment in any other clinical trial throughout the study period

10. Lack of parent-legal guardian informed consent

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care


Intervention

Other:
Probiotic
Standard treatment plus probiotic
Placebo
Standard treatment plus placebo

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
IBSS Biomed S.A. Ministry of Science and Higher Education, Poland

Outcome

Type Measure Description Time frame Safety issue
Primary Gastrointestinal tract colonisation Bacteriological tests involved quantitative and qualitative assessment of neonatal gut flora during clinical follow-up. Bacterial populations of Lactobacillus and Bifidobacterium as well as pathogenic bacteria were assesed.
Stool samples were collected at 7-day intervals (±2 days) in the period of investigational product intake, and on Day 7 (±2 days) after the last dose of the investigational product.
Assesed on days 1, 7, 14, 21, 28, 35, 42 and 49 (assesed weekly within eight weeks) Yes
Primary Feeding intolerance episodes (including: gastric residuals, vomiting, regurgitation of food, abdominal distension, abdominal rigidity, gut motility disorders) Clinical parameters were evaluated throughout the period of care according to standard neonatal care procedures. Assesed on a daily basis (from 1 to 42 and on day 49) Yes
Primary Incidence and type of adverse events and serious adverse events with special regard to sepsis caused by bacteria contained in investigational product. Safety was evaluated by determining whether investigational product in VLBW preterm neonates increases AE/SAE incidence and influences the type of adverse events and serious adverse events as compared to placebo with special regard to sepsis caused by bacteria contained in investigational product . Assesed on a daily basis (from 1 to 42 and on day 49) Yes
Secondary Late onset sepsis caused by Gram positive or Gram negative bacteria Sepsis was confirmed by positive blood cultures. Clinical parameters were evaluated throughout the period of care according to standard neonatal care procedures. Assesed on a daily basis (from 1 to 42 and on day 49) Yes
Secondary Gastrointestinal perforation Clinical parameters were evaluated throughout the period of care according to standard neonatal care procedures. Assesed on a daily basis (from 1 to 42 and on day 49) Yes
Secondary Duration of total parenteral nutrition (days) Duration of total parenteral nutrition (hyperalimentation) was evaluated until full enteral nutrition is restored. Assesed on a daily basis (from 1 to 42 and on day 49) Yes
Secondary Duration (days) of absence of enteral nutrition due to gastrointestinal disorders Clinical parameters were evaluated throughout the period of care according to standard neonatal care procedures. Assesed on a daily basis (from 1 to 42 and on day 49) Yes
Secondary Duration (days) of absence of enteral nutrition for reasons other than gastrointestinal disorders Clinical parameters were evaluated throughout the period of care according to standard neonatal care procedures. Assesed on a daily basis (from 1 to 42 and on day 49) Yes
Secondary Weight, length and head circumference Weight, length and head circumference were evaluated throughout the period of care according to standard neonatal care procedures. Weight was measured once daily, head circumference was measured once a week, and body length was measured on Day 1 and on Day 7 (±2 days) from the last dose (or until the patient was discharged or withdrawn from the study) Yes
Secondary NEC - intensity and severity Severity of neonatal necrotizing enterocolitis was determined according Bell's criteria. Clinical parameters were evaluated throughout the period of care according to standard neonatal care procedures. Assesed on a daily basis (from 1 to 42 and on day 49) Yes
Secondary Mortality rate, with a focus on deaths attributed to NEC and sepsis Clinical parameters were evaluated throughout the period of care according to standard neonatal care procedures. Assesed on a daily basis (from 1 to 42 and on day 49) Yes
Secondary Duration of hospitalization (days) (until discharge) Duration of hospitalization was investigated from the date of patient enrolment until discharge. Assesed on a daily basis (from 1 to 42 and on day 49) Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05544097 - Spectral Analysis of Bowel Sounds in Preterm Babies of Less Than 32 Weeks of Amenorrhea (WA) as Predictive Factor of Enterocolitis N/A
Recruiting NCT03210831 - Early Predictors of Necrotizing Enterocolitis in Neonates
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Recruiting NCT02552706 - The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis N/A
Completed NCT02400697 - Placental Transfusion Project for Preterm Infants N/A
Completed NCT01751477 - Infloran® for Prevention of Necrotizing Enterocolitis N/A
Terminated NCT01156480 - Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants N/A
Completed NCT00787124 - Transfusions and Nitric Oxide Level in Preterm Infants
Unknown status NCT00254176 - Cysteine Supplementation in Critically Ill Neonates Phase 2/Phase 3
Recruiting NCT01441739 - Intestinal Failure in Necrotising Enterocolitis N/A
Recruiting NCT03869827 - Necrotizing Enterocolitis in Fetuses With Intrauterine Growth Restriction
Recruiting NCT04074824 - A Genome-Wide Association Study for Neonatal Diseases
Terminated NCT03320785 - Circulating Markers in Preterm Infants With Perinatal and Neonatal Inflammation
Active, not recruiting NCT03554278 - Alteration of Stool Microbiota in Preterm Infants With Anemia
Not yet recruiting NCT04541771 - The Role of Lactobacillus Reuteri in Preventing Necrotizing Enterocolitis (NEC) in Pre-term Infants Phase 2
Not yet recruiting NCT03700957 - The Impact of Docosahexaenoic Acid on the Prevention of Necrotizing Enterocolitis in Preterm Neonates N/A
Completed NCT03551600 - Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus
Completed NCT01745510 - Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm Neonates Phase 1/Phase 2
Unknown status NCT01807858 - The Effects of Synbiotics on Morbidity and Mortality in Preterm Infants N/A
Completed NCT01735578 - Splanchnic Tissue Oxygenation During Enteral Feedings in Anemic Premature Infants at Risk for Necrotizing Enterocolitis N/A